

Marianna Amboni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5740396/publications.pdf>

Version: 2024-02-01

92
papers

4,439
citations

94269

37
h-index

114278

63
g-index

92
all docs

92
docs citations

92
times ranked

5847
citing authors

#	ARTICLE	IF	CITATIONS
1	Cognitive contributions to gait and falls: Evidence and implications. <i>Movement Disorders</i> , 2013, 28, 1520-1533.	2.2	390
2	Mutation in the <i>SYNJ1</i> Gene Associated with Autosomal Recessive, Early-Onset Parkinsonism. <i>Human Mutation</i> , 2013, 34, 1208-1215.	1.1	276
3	The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa. <i>Brain</i> , 2014, 137, 2731-2742.	3.7	251
4	Resting-state brain connectivity in patients with Parkinson's disease and freezing of gait. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 781-787.	1.1	226
5	Resting-state functional connectivity associated with mild cognitive impairment in Parkinson's disease. <i>Journal of Neurology</i> , 2015, 262, 425-434.	1.8	175
6	The Heterogeneity of Early Parkinson's Disease: A Cluster Analysis on Newly Diagnosed Untreated Patients. <i>PLoS ONE</i> , 2013, 8, e70244.	1.1	150
7	Mild Cognitive Impairment in newly diagnosed Parkinson's disease: A longitudinal prospective study. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1219-1226.	1.1	113
8	Future thinking in Parkinson's disease: An executive function?. <i>Neuropsychologia</i> , 2012, 50, 1494-1501.	0.7	108
9	Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 489-493.	1.1	97
10	Hearing impairment in Parkinson's disease: Expanding the nonmotor phenotype. <i>Movement Disorders</i> , 2012, 27, 1530-1535.	2.2	93
11	Pisa syndrome in Parkinson's disease and parkinsonism: clinical features, pathophysiology, and treatment. <i>Lancet Neurology</i> , The, 2016, 15, 1063-1074.	4.9	86
12	Ropinirole as a Treatment of Restless Legs Syndrome in Patients on Chronic Hemodialysis. <i>Clinical Neuropharmacology</i> , 2004, 27, 178-181.	0.2	84
13	A neuropsychological longitudinal study in Parkinson's patients with and without hallucinations. <i>Movement Disorders</i> , 2007, 22, 2418-2425.	2.2	84
14	Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 1034-1038.	1.1	83
15	Gender differences in non-motor symptoms in early, drug naïve Parkinson's disease. <i>Journal of Neurology</i> , 2013, 260, 2849-2855.	1.8	83
16	<i>GBA</i> -Related Parkinson's Disease: Dissection of Genotype-Phenotype Correlates in a Large Italian Cohort. <i>Movement Disorders</i> , 2020, 35, 2106-2111.	2.2	83
17	Cortical thickness changes in patients with Parkinson's disease and impulse control disorders. <i>Parkinsonism and Related Disorders</i> , 2016, 24, 119-125.	1.1	76
18	Vestibular impairment and adaptive postural imbalance in parkinsonian patients with lateral trunk flexion. <i>Movement Disorders</i> , 2011, 26, 1458-1463.	2.2	75

#	ARTICLE	IF	CITATIONS
19	Apathy in untreated, de novo patients with Parkinson's disease: validation study of Apathy Evaluation Scale. <i>Journal of Neurology</i> , 2014, 261, 2319-2328.	1.8	74
20	A Four-Year Longitudinal Study on Restless Legs Syndrome in Parkinson Disease. <i>Sleep</i> , 2016, 39, 405-412.	0.6	73
21	A two-year follow-up study of executive dysfunctions in Parkinsonian patients with freezing of gait at onset. <i>Movement Disorders</i> , 2010, 25, 800-802.	2.2	71
22	Neuropsychological correlates of theory of mind in patients with early Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 98-105.	2.2	67
23	Gait patterns in parkinsonian patients with or without mild cognitive impairment. <i>Movement Disorders</i> , 2012, 27, 1536-1543.	2.2	66
24	Do Subjective Memory Complaints Herald the Onset of Mild Cognitive Impairment in Parkinson Disease?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2014, 27, 276-281.	1.2	64
25	Clinical clusters and dopaminergic dysfunction in de-novo Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 137-140.	1.1	62
26	Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients. <i>Journal of Neurology</i> , 2012, 259, 1808-1813.	1.8	60
27	Gender differences in non-motor symptoms in early Parkinson's disease: A 2-years follow-up study on previously untreated patients. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 850-854.	1.1	60
28	Using gait analysis parameters to classify Parkinsonism: A data mining approach. <i>Computer Methods and Programs in Biomedicine</i> , 2019, 180, 105033.	2.6	54
29	Resting-state brain networks in patients with Parkinson's disease and impulse control disorders. <i>Cortex</i> , 2017, 94, 63-72.	1.1	53
30	Parkinsonism and essential tremor in a family with pseudo-dominant inheritance of PARK2: An FP-CIT SPECT study. <i>Movement Disorders</i> , 2007, 22, 559-563.	2.2	46
31	Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients. <i>Journal of Neurology</i> , 2013, 260, 438-444.	1.8	46
32	Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naive Parkinson's disease. <i>Journal of Neurology</i> , 2013, 260, 1724-1730.	1.8	45
33	Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. <i>Parkinsonism and Related Disorders</i> , 2017, 38, 90-92.	1.1	44
34	Impact of anxiety, apathy and reduced functional autonomy on perceived quality of life in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 43, 114-117.	1.1	43
35	The use of University of Pennsylvania Smell Identification Test in the diagnosis of Parkinson's disease in Italy. <i>Neurological Sciences</i> , 2014, 35, 379-383.	0.9	42
36	Gender and non motor fluctuations in Parkinson's disease: A prospective study. <i>Parkinsonism and Related Disorders</i> , 2016, 27, 89-92.	1.1	42

#	ARTICLE	IF	CITATIONS
37	Nonmotor predictors for levodopa requirement in de novo patients with Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 373-378.	2.2	41
38	Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson's disease. <i>Journal of Neurology</i> , 2014, 261, 2112-2118.	1.8	37
39	Why do some Friedreich's ataxia patients retain tendon reflexes?. <i>Journal of Neurology</i> , 1999, 246, 353-357.	1.8	36
40	Reversible Pisa syndrome in patients with Parkinson's disease on rasagiline therapy. <i>Movement Disorders</i> , 2011, 26, 2578-2580.	2.2	36
41	Lower serum uric acid is associated with mild cognitive impairment in early Parkinson's disease: a 4-year follow-up study. <i>Journal of Neural Transmission</i> , 2016, 123, 1399-1402.	1.4	36
42	Is serum uric acid related to non-motor symptoms in de-novo Parkinson's disease patients?. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 772-775.	1.1	32
43	Step length predicts executive dysfunction in Parkinson's disease: a 3-year prospective study. <i>Journal of Neurology</i> , 2018, 265, 2211-2220.	1.8	32
44	Serum IGF-1 is associated with cognitive functions in early, drug-naïve Parkinson's disease. <i>PLoS ONE</i> , 2017, 12, e0186508.	1.1	30
45	Side of onset does not influence cognition in newly diagnosed untreated Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 256-259.	1.1	28
46	Association between dopaminergic dysfunction and anxiety in de novo Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 37, 106-110.	1.1	28
47	Cognitive correlates of "pure apathy" in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 53, 101-104.	1.1	27
48	Machine Learning Approaches in Parkinson's Disease. <i>Current Medicinal Chemistry</i> , 2021, 28, 6548-6568.	1.2	27
49	Multiple system atrophy is associated with changes in peripheral insulin-like growth factor system. <i>Movement Disorders</i> , 2010, 25, 2621-2626.	2.2	25
50	Linguistic, psychometric validation and diagnostic ability assessment of an Italian version of a 19-item wearing-off questionnaire for wearing-off detection in Parkinson's disease. <i>Neurological Sciences</i> , 2012, 33, 1319-1327.	0.9	25
51	Screening LRRK2 gene mutations in patients with Parkinson's disease in Ghana. <i>Journal of Neurology</i> , 2012, 259, 569-570.	1.8	24
52	Caffeine consumption and the 4-year progression of de novo Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 32, 116-119.	1.1	24
53	Bisphenol A glucuronidation in patients with Parkinson's disease. <i>NeuroToxicology</i> , 2017, 63, 90-96.	1.4	24
54	Interoceptive processing deficit: A behavioral marker for subtyping Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 53, 64-69.	1.1	24

#	ARTICLE	IF	CITATIONS
55	Intraocular pressure and choroidal thickness postural changes in multiple system atrophy and Parkinson's disease. <i>Scientific Reports</i> , 2021, 11, 8936.	1.6	24
56	Effect of Global Postural Rehabilitation program on spatiotemporal gait parameters of parkinsonian patients: a three-dimensional motion analysis study. <i>Neurological Sciences</i> , 2012, 33, 1337-1343.	0.9	23
57	Short-latency afferent inhibition in patients with Parkinson's disease and freezing of gait. <i>Journal of Neural Transmission</i> , 2015, 122, 1533-1540.	1.4	22
58	Assessment of apathy minimising the effect of motor dysfunctions in Parkinson's disease: a validation study of the dimensional apathy scale. <i>Quality of Life Research</i> , 2017, 26, 2533-2540.	1.5	22
59	Anxiety in early Parkinson's disease: Validation of the Italian observer-rated version of the Parkinson Anxiety Scale (OR-PAS). <i>Journal of the Neurological Sciences</i> , 2016, 367, 158-161.	0.3	21
60	Machine learning can detect the presence of Mild cognitive impairment in patients affected by Parkinson's Disease. , 2020, , .		20
61	Classifying Different Stages of Parkinson's Disease Through Random Forests. <i>IFMBE Proceedings</i> , 2020, , 1155-1162.	0.2	20
62	Quitting smoking: An early non-motor feature of Parkinson's disease?. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 216-220.	1.1	19
63	Music Therapy for Motor and Nonmotor Symptoms of Parkinson's Disease: A Prospective, Randomized, Controlled, Single-Blinded Study. <i>Journal of the American Geriatrics Society</i> , 2016, 64, e36-9.	1.3	16
64	Gait analysis may distinguish progressive supranuclear palsy and Parkinson disease since the earliest stages. <i>Scientific Reports</i> , 2021, 11, 9297.	1.6	16
65	Exercise dependence induced by pramipexole in Parkinson's Disease—A Case Report. <i>Movement Disorders</i> , 2010, 25, 2893-2894.	2.2	13
66	How does smoking affect olfaction in Parkinson's disease?. <i>Journal of the Neurological Sciences</i> , 2014, 340, 215-217.	0.3	13
67	Parkinson's disease in sub-Saharan Africa: step-by-step into the challenge. <i>Neurodegenerative Disease Management</i> , 2011, 1, 193-202.	1.2	11
68	Serum uric acid is associated with apathy in early, drug-naïve Parkinson's disease. <i>Journal of Neural Transmission</i> , 2016, 123, 371-377.	1.4	9
69	Gait Analysis in Progressive Supranuclear Palsy Phenotypes. <i>Frontiers in Neurology</i> , 2021, 12, 674495.	1.1	8
70	Motor dual task with eyes closed improves postural control in patients with functional motor disorders: A posturographic study. <i>Gait and Posture</i> , 2021, 88, 286-291.	0.6	8
71	Parkinson's disease management and impulse control disorders: current state and future perspectives. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 495-508.	1.4	7
72	Classifying patients affected by Parkinson's disease into freezers or non-freezers through machine learning. , 2020, , .		7

#	ARTICLE	IF	CITATIONS
73	Vitamin D as a possible biomarker of mild cognitive impairment in parkinsonians. <i>Aging and Mental Health</i> , 2021, 25, 1998-2002.	1.5	7
74	Metabolomics in Parkinson's disease. <i>Advances in Clinical Chemistry</i> , 2021, 104, 107-149.	1.8	7
75	Relationship Between Orthostatic Hypotension and Cognitive Functions in Multiple System Atrophy: A Longitudinal Study. <i>Frontiers in Neurology</i> , 2021, 12, 711358.	1.1	7
76	Mild Cognitive Impairment Subtypes Are Associated With Peculiar Gait Patterns in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 781480.	1.7	7
77	Pallidal stimulation in atypical pantothenate kinase-associated neurodegeneration: Six-year follow-up. <i>Movement Disorders</i> , 2014, 29, 276-277.	2.2	6
78	Valproate-induced Generalized Choreoathetosis. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 271-272.	0.8	6
79	Comment on Szewczyk-Krolikowski et al.: The influence of age and gender on motor and non-motor features of early Parkinson's disease: Initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1319-1320.	1.1	5
80	Validation of the Italian version of the PSP Quality of Life questionnaire. <i>Neurological Sciences</i> , 2019, 40, 2587-2594.	0.9	5
81	Validation of the Italian version of carers' quality-of-life questionnaire for parkinsonism (PQoL). <i>Tj ETQq1 1 0.784314 rgBT₅Overlo</i>	0.9	5
82	The "eye of the tiger" sign in pure akinesia with gait freezing. <i>Neurological Sciences</i> , 2011, 32, 703-705.	0.9	4
83	Prospective memory in Parkinson's disease: the role of the motor subtypes. <i>Journal of Neurology</i> , 2019, 266, 2505-2511.	1.8	4
84	Prevalence of heterozygous mutations in Niemann-Pick type C genes in a cohort of progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2020, 79, 9-10.	1.1	4
85	Segmental progression of cardinal motor symptoms in Parkinson's disease: A pilot study suggesting a practical approach to rate disease course in the early stages. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1143-1148.	1.1	3
86	The role of the motor subtypes on the relationship between anxiety and cognitive dysfunctions in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2020, 127, 893-898.	1.4	3
87	Interplay between gait and neuropsychiatric symptoms in Parkinson's Disease. <i>European Journal of Translational Myology</i> , 2022, 32, .	0.8	3
88	A quantitative analysis of muscular co-activation on EMG signals in spastic patients treated with Botulinum toxin. , 2020, , .		1
89	Neuropsychological correlates of prospective memory: A comparison between tremor-dominant Parkinson's disease and cervical dystonia. <i>Journal of Clinical Neuroscience</i> , 2021, 87, 156-161.	0.8	1
90	Step length predicts executive dysfunction in Parkinson's disease: a 3-year prospective study. , 2018, 265, 2211.		1

#	ARTICLE	IF	CITATIONS
91	Olfaction in Homozygous and Heterozygous <scp>SYNJ</scp> 1 Arg258Gln Mutation Carriers. Movement Disorders Clinical Practice, 2015, 2, 413-416.	0.8	0
92	Italian survey on intraduodenal levodopa gel treatment in advanced Parkinson disease: State of the art 10 years after marketing. Parkinsonism and Related Disorders, 2016, 22, e97-e98.	1.1	0